Onze stand demonstreert naadloos verbonden automatisering en intelligente software, aangestuurd door AI

WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific, wereldleider in wetenschappelijke dienstverlening, sponsort deze week Lab of the Future Europe in Amsterdam en laat zien hoe het Thermo Fisher Connect Platform van het bedrijf laboratoria kan integreren en toekomstbestendig kan maken.

Van digitale ambitie naar geautomatiseerde intelligentie

In de farmaceutische en life sciences-sector is digitale transformatie niet langer een kwestie van óf, maar van hoe snel. Veel laboratoria blijven vastzitten in een vicieuze cirkel van technische schuld en schaduw-IT.

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.

Bekijk het oorspronkelijke bericht op businesswire.com: https://www.businesswire.com/news/home/20250930055936/nl/

Contacts

Informatie van contactpersonen voor de media:

Alex Runner

Thermo Fisher Scientific

alex.runner@thermofisher.com

Jessika Parry, Greenough

419-266-4016

jparry@greenoughagency.com

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Elemental Machines, een pionier op het gebied van intelligente oplossingen voor laboratoriumactiviteiten, heeft aangekondigd dat het is erkend in het nieuwste Gartner^® Hype Cycle rapport voor het Internet of Things, 2025. Dit rapport evalueert innovaties en trends die van invloed zijn op Internet of Things-leiders.

Elemental Machines is van mening dat het onderzoek leiders helpt bij het meten van de technologische volwassenheid en acceptatie voor de planning van de roadmap.

“Vermelding in het Gartner Hype Cycle-rapport is een duidelijk teken van het momentum dat Elemental Machines heeft opgebouwd,” aldus Rob Estrella, CEO van Elemental Machines. “Dit is een waardevolle kans voor ons om te laten zien hoe ons werk echte klantproblemen oplost en resultaten verbetert, terwijl we tegelijkertijd de toekomst van verbonden labtechnologie en operationele intelligentie vormgeven.”

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.

Bekijk het oorspronkelijke bericht op businesswire.com: https://www.businesswire.com/news/home/20250930989484/nl/

Contacts

CONTACTPERSOON VOOR DE MEDIA:
Gabe Martinez

SCORR Marketing

+1 308.338.2304

pr@scorrmarketing.com

Tactiele cartografie: kaarten voor mensen met een visuele beperking tonen nieuwe inzichten in ontwerp en methoden voor het toegankelijk presenteren van geografische informatie

REDLANDS, Calif.–(BUSINESS WIRE)– Esri, wereldwijd marktleider op het gebied van locatie-informatie, publiceert Tactile Mapping: Cartography for People with Visual Impairments. Deze verzameling door experts geschreven hoofdstukken, casestudy’s en gebruikersverhalen laat cartografie zien met een verbeterde toegang voor mensen met een visuele beperking.

Tactiele kaarten bieden meer onafhankelijkheid en inclusie voor blinden, maar veel van het onderzoek op dit gebied is nog steeds niet toegankelijk voor een breder publiek.

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.

Bekijk het oorspronkelijke bericht op businesswire.com: https://www.businesswire.com/news/home/20250929379033/nl/

Contacts

Jo Ann Pruchniewski

Public Relations, Esri

Mobiel: 301-693-2643

E-mail: jpruchniewski@esri.com

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Elemental Machines, a pioneer in intelligent lab operations solutions, announced it has been recognized in the latest Gartner^® Hype Cycle for the Internet of Things, 2025 report. This report evaluates innovations and trends impacting Internet of Things leaders.

Elemental Machines believes the research helps leaders gauge technology maturity and adoption for road map planning.

“Being mentioned in the Gartner Hype Cycle report is a clear sign of the momentum Elemental Machines has built,” said Rob Estrella, CEO of Elemental Machines. “This is a valuable opportunity for us to showcase how our work is solving real customer problems and improving outcomes, while shaping the future of connected lab technology and operational intelligence.”

Elemental Machines’ platform spans data management, security, asset utilization, and integration across laboratory hardware and software to help convert sensor data into operational intelligence for regulated lab and manufacturing environments.

“The mention validates both the technology and Elemental Machines’ vision as the market moves from hype to proven, high-impact deployments,” said Sridhar Iyengar, Founder and Chief Strategy & Technology Officer at Elemental Machines.

Gartner Attribution & Disclaimer

Gartner, Hype Cycle for IoT, 2025, Kameron Chao, Alfonso Velosa, Pablo Arriandiaga, Scot Kim, Emil Berthelsen, 25 July 2025

GARTNER AND HYPE CYCLE are a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Elemental Machines

Elemental Machines’ Intelligent Operations Platform transforms raw lab and facility data into intelligence you can act on. Built by scientists and engineers who understand the demands of modern research and manufacturing environments, we connect the physical and digital worlds to simplify, optimize, and future-proof operations. From incubators to enterprise-level sites, our ecosystem combines wireless sensors, utilization tracking, custom dashboards, interactive floorplans, business intelligence tools, and seamless integrations with systems like LIMS, MES, QMS, CMMS, and ELNs, giving teams complete visibility, predictive insights, and audit-ready compliance tools. Leaders in science, facilities, and technology worldwide trust Elemental Machines to help them act faster, reduce operational risk, and shift from reactive to proactive management. With the industry’s most expansive integration library and a robust partner ecosystem, we empower organizations to accelerate innovation, ensure scientific integrity, and get more value from every asset.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250930723682/en/

Contacts

MEDIA CONTACT:
Gabe Martinez

SCORR Marketing

+1 308.338.2304

pr@scorrmarketing.com

Our booth will demonstrate seamlessly connected automation and intelligent software powered by AI

WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific, the world leader in serving science, is sponsoring Lab of the Future Europe this week in Amsterdam, The Netherlands, and will demonstrate how the company’s Thermo Fisher Connect Platform can integrate and future-proof laboratories.

From Digital Ambition to Automated Intelligence

In pharma and life sciences, digital transformation is no longer a question of if — but how fast. Many labs remain stuck in a cycle of technical debt and shadow IT. By leveraging Thermo Fisher’s capabilities in digital solutions and advanced automation, the Connect Platform moves laboratories from basic digitization to full orchestration. It connects instruments, systems and data across labs to create a unified environment and increase productivity.

“Our Mission at Thermo Fisher Scientific is to enable our customers to make the world healthier, cleaner and safer, and this means helping scientists achieve their goals more effectively, moving beyond routine tasks to focus on what really matters: discovery, insight and impact,” said Mark Fish, vice president and general manager of Digital Science and Automation Solutions, Thermo Fisher Scientific.

At Lab of the Future Europe, Thermo Fisher is demonstrating how that Mission informs our Connect Platform to tangibly upgrade labs across the globe. Attendees can engage with the company in the following ways in Amsterdam:

• Listen to a keynote presentation by Mark Fish: “Key Ingredients for Building the Automated Digital Labs of the Future.” (Tuesday, September 30)
• Attend a track presentation by Martin Hornshaw, senior director, scientific collaboration, enterprise science and innovation partnerships: “Customer Case Studies, Enterprise Science and Innovation for Scaled Business Outcomes.” (Wednesday, October 1)
• Visit us at booth C3 to learn more about our digital and automation offerings.

The Power of Partnership

Also announced this week is a strategic partnership between Thermo Fisher and BenchSci, a pioneer in AI for life sciences research. The companies will develop AI-powered research tools and digital capabilities to accelerate experimental design and improve R&D productivity for scientists and researchers. Visit our booth at Lab of the Future Europe to learn more.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250930361757/en/

Contacts

Media Contact Information:

Alex Runner

Thermo Fisher Scientific

alex.runner@thermofisher.com

Jessika Parry, Greenough

419-266-4016

jparry@greenoughagency.com

Partnership Expands Access to Scalable, High-Quality Single Cell Analysis for Researchers

SEATTLE–(BUSINESS WIRE)– Parse Biosciences, the leader in scalable and accessible single cell sequencing, is pleased to welcome the Netherlands-based Single Cell Discoveries as the newest member of its Certified Service Provider (CSP) Program. As a certified provider, Single Cell Discoveries will expand access to Parse’s single cell technology, pairing it with a team uniquely dedicated to single cell science to support researchers across Europe and worldwide.

Introduced in 2024, the CSP Program connects researchers with rigorously vetted partners for outsourcing single cell projects of any size. By maintaining exacting standards for data quality, scalability, and service, the program helps labs accelerate discovery with confidence.

“Becoming the first service provider in Europe to join Parse’s Certified Service Provider program reflects our commitment to leadership in single cell science,” said Mauro Muraro, PhD, co-founder and CEO of Single Cell Discoveries. “Partnering with Parse’s scalable, fixation-friendly technology allows us to deliver high-quality results at the pace modern research demands, whether for a focused pilot or an atlas-scale study.”

“Expanding our CSP network ensures researchers have reliable, regional access to best-in-class single cell services,” said Alex Rosenberg, CEO and co-founder of Parse Biosciences. “With Single Cell Discoveries joining the program, scientists gain a trusted partner whose focus has always been single cell, now complemented by the scalability and precision that Parse enables.”

About Parse Biosciences

Parse Biosciences is a global life sciences company dedicated to accelerating advancements in human health and scientific research. By empowering researchers to conduct single cell sequencing with unparalleled scale and simplicity, Parse’s innovative solutions are driving breakthroughs in cancer treatment, tissue repair, stem cell therapy, and more. Built upon transformative technology developed at the University of Washington, Parse Biosciences has raised over $100 million and is used by over 3,000 labs worldwide. Its expanding product portfolio includes Evercode Whole Transcriptome, Evercode TCR, Evercode BCR, CRISPR Detect, Gene Select, and Trailmaker for advanced data analysis. Headquartered in Seattle’s vibrant South Lake Union district, Parse Biosciences recently inaugurated a 34,000-square-foot facility featuring state-of-the-art laboratories to support its mission of advancing global research. www.parsebiosciences.com

About Single Cell Discoveries

Single Cell Discoveries is a leading contract research organization (CRO) specializing in single-cell sequencing, spatial transcriptomics, and multiomic applications. Headquartered in Utrecht, the Netherlands, the company partners with biopharmaceutical organizations and academic institutions worldwide to accelerate drug discovery and innovation. With more than a decade of expertise, over 1,000 projects completed, and millions of single cells sequenced across 50+ species, Single Cell Discoveries delivers high-impact transcriptomic insights with precision and scale. Leveraging state-of-the-art laboratory facilities, advanced sequencing platforms, and tailored bioinformatics support, the company combines high-throughput automation, fast turnaround times, and excellence in single-cell preparation, which are three factors essential for successful and reproducible outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250930263922/en/

Contacts

Kaitie Kramer

kkramer@parsebiosciences.com | 858.504.0455

MONTREAL–(BUSINESS WIRE)– Dentalis Animal Health Inc. kondigt met trots een mijlpaal in de veterinaire tandheelkunde aan: het bedrijf heeft vijf prestigieuze Veterinary Oral Health Council (VOHC®) Seals of Approval ontvangen voor zijn tandsticks, tandpasta en combinatieproducten voor honden.

Deze mijlpaal bevestigt de positie van Dentalis als wereldwijde leider in mondverzorging voor huisdieren, met oplossingen die effectief, smakelijk en schaalbaar zijn voor elke hond, groot of klein.

De volgende producten zijn goedgekeurd:

• Dentalis Canine Stick (20 g en 30 g) – Uiterst smakelijke, natuurlijke dental sticks die het VOHC®-keurmerk hebben ontvangen. Ondersteund door wetenschappelijke data en gepositioneerd om de nieuwe Best in Class-standaard te worden in veterinaire mondverzorging.

• Dentalis Tandpasta – De tweede tandpasta ooit erkend door VOHC®, waarmee een nieuwe norm wordt gesteld in de mondverzorging voor dieren.

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.

Bekijk het oorspronkelijke bericht op businesswire.com: https://www.businesswire.com/news/home/20250926346733/nl/

Contacts

Media: David Hauptman

CEO Dentalis Animal Health Inc.

E-mail: david@dentalis.ca
Telefoon: +1 (514) 578-0345

Website: www.dentalis.ca

Nieuwe merknaam met bewezen staat van dienst – door EMA en FDA gecontroleerde sites met gespiegelde capaciteit in Polen bieden een versnelde route van ontwikkeling naar commercialisatie.

GDAŃSK & WARSCHAU-DUCHNICE, Polen–(BUSINESS WIRE)– Rezon Bio heeft vandaag aangekondigd dat het van start gaat als Europese contractontwikkelings- en productieorganisatie (CDMO) voor biologische geneesmiddelen. Het bedrijf betreedt de markt als een nieuw merk, maar bouwt voort op een bewezen staat van dienst op het gebied van de ontwikkeling van biologische geneesmiddelen, van gen tot wereldwijde commercialisering, via gevestigde partners.

Met twee ultramoderne faciliteiten in Gdańsk en Warschau-Duchnice biedt Rezon Bio klanten een totaaloplossing, van de ontwikkeling van cellijnen tot goede productiepraktijken (GMP) en commerciële levering.

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.

Bekijk het oorspronkelijke bericht op businesswire.com: https://www.businesswire.com/news/home/20250929283790/nl/

Contacts

Mediacontact voor Rezon Bio:
Natalia Kwiecień

natalia.kwiecien@rezonbio.com
Tel: +48 725 800 893

• Het AI-first engineeringplatform meldt een stijging van 100% in het gebruik door bedrijven, waardoor OEM’s toekomstbestendig kunnen ontwerpen met AI-gestuurde, door mensen geleide workflows.
• Tot de klanten van dit jaar behoren Renault, Leonardo, GE Vernova U.S., Hanwha Ocean, Sumitomo Wiring Systems, SPAL Automotive, Kautex en Multi-Wing.

LAUSANNE, Zwitserland–(BUSINESS WIRE)– Neural Concept, de toonaangevende AI-first engineeringomgeving voor productontwikkeling, meldt vandaag een sterke versnelling in klantengroei en platformadoptie tot nu toe in 2025. Als reactie op de grote vraag breidt het bedrijf zijn teams uit in Europa, Noord-Amerika en Azië.

Dit persbericht bevat multimedia. Bekijk hier het volledige persbericht: https://www.businesswire.com/news/home/20250926625427/nl/

Neural Concept’s Design Lab: a native co-pilot experience where engineers and designers collaborate, bringing real-time physics into the design environment.

Het gebruik van het platform van Neural Concept door bedrijven is sinds januari 2025 verdubbeld, ondersteund door een stijging van 40% in bijverkoop, nu klanten zijn overgestapt van op maat gemaakte applicaties naar bedrijfsbreed gebruik.

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.

Bekijk het oorspronkelijke bericht op businesswire.com: https://www.businesswire.com/news/home/20250926625427/nl/

Contacts

Contact voor de media
ThoughtLDR voor Neural Concept

neuralconcept@thoughtldr.com
+44 (0)7553600128

New brand with proven track record – EMA and FDA-audited mirrored-capability sites in Poland provide an accelerated path from development to commercialization.

GDAŃSK & WARSAW-DUCHNICE, Poland–(BUSINESS WIRE)– Rezon Bio today announced its launch as a European contract development and manufacturing organization (CDMO) for biologics. It enters the market as a new brand, but builds on a proven legacy of advancing biologics from gene to global commercialization through established partners.

With two state-of-the-art facilities in Gdańsk and Warsaw-Duchnice, Rezon Bio offers clients an end-to-end path from cell line development through GMP manufacturing and commercial supply. Both sites feature mirrored capabilities, enabling seamless technology transfer and flexible scale-up. The infrastructure is based on single-use systems for faster product turnover and accelerated delivery. Development platforms, including AMBR systems, are optimized to shorten early development cycles and de-risk scale-up.

“Rezon Bio is a new name, but it stands on a track record that already includes building a broad biosimilars portfolio – with two products launched worldwide through our partners,” said Adriana Kiędzierska-Mencfeld, the newly appointed CEO of Rezon Bio. “That experience is the foundation of our new CDMO offering. We know the challenges of developing and launching biologics because we have been through them ourselves. Now we are here to make that journey easier, faster and cost-efficient for our clients.”

Rezon Bio combines European location advantages with Poland’s strong biopharma talent base and cost structure. This allows the company to deliver competitive economics while maintaining uncompromising quality. Both facilities have been audited by the EMA and FDA, and Rezon Bio operates under global compliance frameworks.

Digital innovation is central to the model. Process modeling, AI-enabled systems, and project transparency tools help clients track milestones, anticipate risks, and manage comparability – designed to reduce delays and compress time to market.

“We will disrupt the European CDMO landscape by being the most cost competitive and reliable partner,” said Konstantin Matentzoglu, Chairman of the Supervisory Board of Rezon Bio. “Our commitment is to accelerate programs while maximizing customer value that benefits patients worldwide. That is our Rezon.”

Rezon Bio’s first industry presence will be at the Festival of Biologics, European Biomanufacturing Summit, CPHI Frankfurt, and BIO-Europe, where its leadership and technical experts will be available for meetings: schedule a meeting with the Rezon Bio Business Development team.

About Rezon Bio

Rezon Bio is a biologics CDMO specializing in mammalian drug substance development and GMP manufacturing, with drug product coordinated via qualified external partners. Headquartered in Poland, the company operates two mirrored-capability facilities in Gdańsk and Warsaw-Duchnice audited by EMA and FDA. Drawing on a legacy of biosimilars development and global commercialization, Rezon Bio combines proven experience, digital transparency, and cost-to-value efficiency to help clients move from concept to market with confidence. Learn more at https://rezonbio.com or schedule a virtual introduction at https://rezonbio.dayschedule.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250929803065/en/

Contacts

Rezon Bio media contact:
Natalia Kwiecień

natalia.kwiecien@rezonbio.com
Tel: +48 725 800 893